Shares of UroGen Pharma (NASDAQ:URGN) lost ~47% on Wednesday after an FDA advisory committee voted against the company’s ...

The FDA ODAC decided that the overall benefit-risk of the investigational therapy UGN-102 is not favorable in patients with recurrent low-grade, intermediate-risk NMIBC.

Dr. Daniel P. Petrylak sits down with CURE during Bladder Cancer Awareness Month to discuss key topics for patients with the ...

Transurethral resection of bladder tumor (TURBT) followed by intravesical Bacillus Calmette-Guérin (BCG) induction and maintenance is the current standard of care for high-risk NMIBC. However ...

Immunotherapy uses your immune system to fight cancer. BCG is a type of intravesical therapy, which means a liquid drug is put directly into your bladder through a catheter (a thin tube), rather ...

It is designed for intravesical dosing and intended to be an in-office ready-to-use therapy that is administered rapidly and requires no anesthesia or new or dedicated equipment to employ.

The standard of care includes complete transurethral resection of bladder tumor, often followed by intravesical therapy such as Bacillus Calmette-Guérin (BCG). However, BCG has a treatment ...

It is designed for intravesical dosing and intended to be an in-office ready-to-use therapy that is administered rapidly and requires no anesthesia or new or dedicated equipment to employ.

NDV-01 is a novel, investigational, sustained-release gemcitabine/docetaxel formulation, designed as a ready-for-use intravesical therapy for the treatment of NMIBC. The U.S. prevalence of NMIBC ...

Results from the Phase IIb SunRISe-1 study demonstrated a one-year duration of response with the TAR-200 intravesical gemcitabine-releasing ... leaving patients with limited alternatives when initial ...

When BCG therapy was combined with chemotherapy and administered at lower doses, fewer treatment-related symptoms and side effects were reported by patients with NMIBC, compared to other BCG ...

Preliminary results from LEGEND: A phase 2 study of detalimogene voraplasmid (EG-70), a novel, non-viral intravesical gene therapy for patients with BCG-unresponsive non-muscle invasive bladder cancer ...